Immunomedics (IMMU) Reports Results of Adding Epratuzumab to Rituximab in Chemotherapy in Aggressive Lymphoma
More News related to IMMU
- Immunomedics Announces First Quarter Fiscal 2010 Results and Clinical Program Developments
- Immunomedics to Present at Upcoming Conferences
- Immunomedics Receives Corporate Award From New Jersey Inventors Hall of Fame
- Immunomedics (IMMU) Awarded 2 Small Business Grants from NIH
- Immunomedics Awarded Three Grants by NIH to Develop New Agents for Imaging and Therapy of Cancer
More News related to FDA
- Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Immunomedics, Inc. (Nasdaq: IMMU) reported that adding epratuzumab to rituximab and combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) to treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) produced promising results. This study was published in an on-line article in Cancer.
Patients received epratuzumab at 360 mg/m2, followed by rituximab at 375 mg/m2, and a standard dose of CHOP every 3 weeks for 6 to 8 cycles. Although, grade 3 or 4 neutropenia was observed in 14 patients (93%), or in 28 of 92 cycles (30%), only 3 patients developed grade 3 or more infection or fever. Eleven patients (73%) required dose reductions mainly secondary to grade 4 neutropenia. No grade 3 antibody infusion-related toxicity was reported.
Related Categories
FDAStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
